ClinicalTrials.gg
Sign In

Lung Diseases clinical trials

The registry lists 1,158 studies for Lung Diseases across more than 10 countries. 182 are recruiting or about to start. 330 of them are mainly about Lung Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 72 narrower conditions too, such as COVID-19: 42,499 studies, 7,564 open.

ClinicalTrials.gov finds 43,397 studies for Lung Diseases. How that becomes 1,158 here

This page counts the studies the registry files under Lung Diseases, and those it files under no condition that list Lung Diseasesthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 43,397Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −38,989Filed under a narrower condition, counted on its own pageCOVID-19 7,533 · Carcinoma, Non-Small-Cell Lung 7,028 · Pulmonary Disease, Chronic Obstructive 5,040 · Asthma 3,881 · Lung Neoplasms 3,422 · Cystic Fibrosis 1,452 · 63 more
  3. −152List Lung Diseases as a condition, but the registry did not file them under itMost often written as “Chronic Lung Disease” (34), “Nontuberculous Mycobacterial Lung Disease” (12), and “Restrictive Lung Disease” (7). The registry filed 65 of them under no condition at all, and the others under other conditions only, most often Diabetes Mellitus (6) and Neoplasms (6).
  4. −3,098Match it another way150 name it in the title, 24 in a keyword, and 2,924 by a synonym or other text the search reads.
  5. 1,158The count on this page

Get an email when these change. Save the Lung Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
705
Recruiting
140
Status unknown
93
Terminated
85
Active, not recruiting
52
Withdrawn
38

Phase

Phase 2
152
Phase 3
139
Phase 1
92
Phase 4
43
Early Phase 1
4

Where

United States
406
France
106
Canada
99
Germany
93
United Kingdom
87
Spain
86

Who runs them

National Heart, Lung, and Blood Institute (NHLBI) (115) · AstraZeneca (43) · Novartis Pharmaceuticals (14) · NYU Langone Health (11) · Johns Hopkins University (10) · Pfizer (9) · Weill Medical College of Cornell University (9) · University of California, San Francisco (9)

What is being tested here

Drugs under test in Lung Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Amikacin315
Moxifloxacin234
BNT162 Vaccine223
Clofazimine212
Bedaquiline212
Linezolid212
Imipenem212
Remdesivir222
Ibuzatrelvir222
SC1011113

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 7 open · Immune checkpoint inhibitors 5 open · Corticosteroids 1 open · Antimuscarinics 6 · Bronchodilators 4

Coming up

23phase 3 studies under way
70studies finish main data collection within a year11 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 140 Lung Diseases studies recruiting now, 76 (54%) set no upper age limit and 28 (20%) stop at 75 or younger. 16 (11%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 27 (19%) take healthy volunteers.

Recruiting studies that take each age, of 140
AgeWomenMen
1012 (9%)12 (9%)
18112 (80%)111 (79%)
30121 (86%)120 (86%)
40132 (94%)131 (94%)
50134 (96%)133 (95%)
65131 (94%)131 (94%)
75122 (87%)122 (87%)
85100 (71%)100 (71%)

Across all 1,158 studies, recruiting or not: 26% stop at 75 or younger and 16% at 65; 29% take children; 2% are for women only and 6% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lung Diseases studies take

Of 52 phase 3 interventional studies under Lung Diseases, half reached primary completion within 32 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 120 mo5–48 · 27 studies——
Phase 1/243 mo24–84 · 16 studies——
Phase 230 mo18–56 · 51 studies21 mo13–39 · 33 studies—
Phase 332 mo21–64 · 52 studies30 mo20–45 · 42 studies—
Phase 427 mo20–50 · 21 studies——
Interventional, no phase22 mo10–47 · 207 studies—22 mo10–47 · 184 studies
Observational36 mo15–82 · 153 studies—40 mo17–95 · 131 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting3

Stopped1

Newly registered6

Show 1 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,158. Browse all 1,158 → or search them.